Viscosupplementation Market Size & Share, by Product (Single Injection, Three Injections, Five Injections); Application (Knee Osteoarthritis, Shoulder Osteoarthritis, Hip Osteoarthritis); Source (Animal, Non-Animal); End-user (Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Retail Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4381
  • Published Date: Feb 17, 2023
  • Report Format: PDF, PPT

Companies Dominating the Viscosupplementation System Landscape

top-features-companies
    • Sanofi S.A.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Anika Therapeutics, Inc.
    • Seikagaku Corporation
    • Smith & Nephew PLC
    • Lifecore Biomedical, Inc.
    • LG Chem Life Sciences Innovation Center, Inc.
    • Fidia Farmaceutici S.p.A.
    • F. Hoffmann-La Roche Ltd
    • Chugai Pharmaceutical Co., Ltd.
    • OrthogenRx, Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Chugai Pharmaceutical Co., Ltd. has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for its osteoporosis treatment Edirol Tablets 0.5 g/0.75 g (generic name: eldecalcitol, hereafter, Edirol Tablet), a vitamin D3 derivative developed by Chugai based on long-standing research into vitamin D.

  • Seikagaku Corporation launched HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Taiwan, through TCM Biotech International Corp. The main ingredient of HyLink is a cross-linked hyaluronate hydrogel derived from Seikagaku's crosslinking technology.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4381
  • Published Date: Feb 17, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing geriatric population and high prevalence of obesity are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023-2033.

High cost of viscosupplementation treatment is estimated to be the growth hindering factor for the market expansion.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Anika Therapeutics, Inc., Seikagaku Corporation, Smith & Nephew PLC, Lifecore Biomedical, Inc., LG Chem Life Sciences Innovation Center, Inc., Fidia Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co., Ltd., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product, application, source, end-user, and by region.

The knee osteoarthritis segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying